Fortress Bio (FBIO) Inches Closer to $3.00 on Major News.

Fortress Bio (FBIO) Inches Closer to $3.00 on Major News. Citius Pharma (CTXR) Inches Closer to the Next Phase III Data Announcement. Citius Pharma Presenting at...
Citius, Biotech Stock Review

Citius (CTXR) Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial

PHASE III PROGRESS October 7th, 2019, Citius Completes 40% - Triggers Data Being Analyzed (is it working?).December 19th, 2019 - Data Analysis Back, Results Positive.February...

Okay, so What’s Next for Citius Pharma (CTXR) $1.16?

Dawson James Broker/Dealer Updates. Price Target Remains at $7.00. "OK, So what’s Next? Topline data from the superior efficacy interim analysis should represent the next...
Citius Pharma

Citius Pharma (CTXR) $1.20. Price Target Upped to $4.00 at HC Wainright.

STREET INSIDER H.C. Wainwright analyst Vernon Bernardino raised the price target on Citius Pharmaceuticals (NASDAQ: CTXR) to $4.00 (from $1.65) while maintaining a Buy rating. The analyst commented,...
coronavirus, biotech stock review

VIDEO: Dyadic (DYAI) CEO Explains What his Industry is Doing to Defeat Coronavirus (FoxNews).

Jan. 27, 2020 - 5:24 - Dyadic International CEO Mark Emalfarb discusses what’s being done to stop the spread of coronavirus and to...
Dyadic

Could Dyadic (DYAI) $5.75 Provide a Solution to Help Mass Produce Vaccines to Battle...

Dyadic (DYAI) has developed a biomanufacturing technology platform, nicknamed C1 which helps to speed the development, lower the manufacturing cost and potentially improve the...
Immunomedics, Biotech Stock Review

Biotech 5 Pack. 5 Biotech Stocks We Expect to Double in 2020.

Our First Newsletter of 2020, We Come out Swinging! Yes, you read it right. Five of our favorite Biotech stocks that have the potential to...
Citius Pharmaceutical, CTXR, Biotech Stock Review

New Report: Citius Pharma (CTXR) Now Our #1 Ranked Idea for 2020.

Citius Pharmaceuticals (CTXR) is hands down one of the most exciting long-term opportunities we have come across since we first launched the Biotech Stock...

Citius Pharma (CTXR) Corporate Presentation (Jan 2020).

In the above graphic, the catheter can get infected by bacteria and most typically see evidence of the infection (see gross graphic below) at...
Mitesco, Biotech Stock Review

Medtech Incubator True Nature | Mitesco (TNTY) Adds Another Heavy Hitter to Board.

True Nature Holding, Inc. DBA Mitesco, Inc. Adds Distinguished Healthcare Executive to Board of Directors. ATLANTA, GA, Jan. 06, 2020 (GLOBE NEWSWIRE) -- via...

Latest article

Jeffrey Gundlach: Reckoning is Coming.

Jeffrey Edward Gundlach is a businessman, fund manager, and philanthropist. He is the founder of DoubleLine Capital, an investment firm. On 11 November 2020, Gundlach remarked in an interview with...

Who’s the Next Eric Sprott?

Eric Sprott, on Who is the Next Eric Sprott! To say Eric Sprott has left a legendary mark on the world of mining investment would...

Perpetua (PPTA) Raises $300 Million.

Not a bad day in Idaho. $300 million banked! We look at the dip as a buying opportunity, as does John Paulson & Co.,...